Various clinical and biological markers including C-reactive protein (CRP), the erythrocyte sedimentation rate (ESR), and the presence of autoantibodies have been identified as risk factors for CRRP in patients with RA, especially those enrolled in clinical trials treated with bDMARDs.15–18. This evidence concerns the gene CRP and rheumatoid arthritis.